You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriflusal
Accession NumberDB08814
TypeSmall Molecule
GroupsApproved
DescriptionApproved by the European Stroke Organization, triflusal is recommended as lone therapy for the secondary prevention of atheroembotic stroke. Triflusal appears to be equally effective with a better safety profile than acetylsalicylic acid plus dypridamole and clopidogrel alone based on a double blind, randomized TACIP and TAPIRSS trials.
Structure
Thumb
Synonyms
Triflusal
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1Z0YFI05OO
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFor the pevention of cardiovascular events such as stroke, for acute treatment of cerebral infarction, myocardial infarction, and for thromboprophylaxis due to atrial fibrillation.
Structured Indications Not Available
PharmacodynamicsTriflusal is an antithrombotic anticoagulant. It irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. Triflusal affects many other targets such as NF kappa B, which is a gene expression regulatory factor for cycloxygenase-a and cytokines. Numerous studies comparing the efficacy and safety profile (i.e. systemic hemorrhage) between triflusal and acetylsalsylic acid has shown either no significant difference or a better effacy and safety profile for triflusal. Triflusal has been shown to protect cerebral tissue due to its inhibition of lipid peroxidation resulting from anoxia-reoxygenation.
Mechanism of actionTriflusal is chemically related to acetylsalicylic acid (ASA) and irreversibly inhibits cycloxygenase-1 (COX-1) in platelets. Acetylation of the active group of COX-1 prevents the formation of thromboxane-B2 in platelets. However, it is unique because it spares the arachidonic acid metabolic pathway in endothelial cells. In addition, it favors the production of nitric oxide, a vasodilator.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinyes
antagonist
HumanP23219 details
Nuclear factor NF-kappa-B p105 subunitProteinyes
antagonist
HumanP19838 details
Nitric oxide synthase, inducibleProteinyes
agonist
HumanP35228 details
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AProteinyes
antagonist
HumanQ9Y233 details
Related Articles
AbsorptionAbsorbed in the small intestine with a bioavailability range from 83% to 100%. There is no significant difference between the absorption of the oral solution and capsule formulation.
Volume of distribution

34L

Protein bindingBinds to plasma proteins almost entirely (99%)
Metabolism

In the liver, triflusal undergoes deacetylation, forming its main metabolite 2-OH-4-trifluoromethyl benzoic acid (HTB).

SubstrateEnzymesProduct
Triflusal
Not Available
2-hydroxy-4-trifluoromethyl benzoic acidDetails
Route of eliminationPrimarily renal.
Half lifeIn healthy human, the half life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.
Clearance

Renal clearance is 0.8 +/- 0.2L/h and 0.18 +/1 0.04L/h for triflusal and HTB, respectively.

ToxicityExcessive bleeding. The risk of bleeding is less than that of acetylsalicylic acid.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabTriflusal may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolTriflusal may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Triflusal is combined with Acetylsalicylic acid.Approved, Vet Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Triflusal.Approved, Investigational
AlteplaseTriflusal may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Triflusal may increase the anticoagulant activities of ALX-0081.Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Triflusal is combined with Aminosalicylic Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Triflusal.Approved
AncrodTriflusal may increase the anticoagulant activities of Ancrod.Investigational
AnistreplaseTriflusal may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanTriflusal may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Triflusal is combined with Apixaban.Approved
AprotininThe therapeutic efficacy of Triflusal can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinTriflusal may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanTriflusal may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinTriflusal may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the anticoagulant activities of Triflusal.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Triflusal is combined with Balsalazide.Approved, Investigational
BatroxobinTriflusal may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminTriflusal may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinTriflusal may increase the anticoagulant activities of Bemiparin.Approved
BeraprostBeraprost may increase the anticoagulant activities of Triflusal.Investigational
BivalirudinTriflusal may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Triflusal.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Triflusal.Approved
CertoparinTriflusal may increase the anticoagulant activities of Certoparin.Approved
CilostazolCilostazol may increase the anticoagulant activities of Triflusal.Approved
Citric AcidTriflusal may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Triflusal.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Triflusal is combined with Collagenase.Approved
Dabigatran etexilateTriflusal may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTriflusal may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTriflusal may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Triflusal.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Triflusal.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Triflusal is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Triflusal is combined with dersalazine.Investigational
DesirudinTriflusal may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseTriflusal may increase the anticoagulant activities of Desmoteplase.Investigational
DextranTriflusal may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Triflusal may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Triflusal may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Triflusal may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolTriflusal may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Triflusal is combined with Diflunisal.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Triflusal.Approved
DitazoleTriflusal may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaTriflusal may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidTriflusal may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTriflusal may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinTriflusal may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Triflusal.Approved, Investigational
eplivanserineTriflusal may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Triflusal.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Triflusal.Approved, Investigational
Ethyl biscoumacetateTriflusal may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FibrinolysinTriflusal may increase the anticoagulant activities of Fibrinolysin.Approved
FluindioneTriflusal may increase the anticoagulant activities of Fluindione.Investigational
FondaparinuxTriflusal may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTriflusal may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateTriflusal may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Triflusal.Approved
HeparinTriflusal may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineTriflusal may increase the anticoagulant activities of Higenamine.Investigational
HirulogTriflusal may increase the anticoagulant activities of Hirulog.Experimental
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Triflusal.Approved
IbudilastIbudilast may increase the anticoagulant activities of Triflusal.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Triflusal.Approved, Nutraceutical
idraparinuxTriflusal may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Triflusal.Approved, Withdrawn
IloprostIloprost may increase the antiplatelet activities of Triflusal.Approved, Investigational
IndobufenTriflusal may increase the anticoagulant activities of Indobufen.Investigational
Kct 0809Triflusal may increase the anticoagulant activities of Kct 0809.Investigational
KetanserinKetanserin may increase the anticoagulant activities of Triflusal.Investigational
LepirudinTriflusal may increase the anticoagulant activities of Lepirudin.Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Triflusal.Approved
MesalazineThe risk or severity of adverse effects can be increased when Triflusal is combined with Mesalazine.Approved
MilrinoneMilrinone may increase the anticoagulant activities of Triflusal.Approved
NadroparinTriflusal may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTriflusal may increase the anticoagulant activities of Nafamostat.Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Triflusal.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Triflusal is combined with NCX 4016.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Triflusal.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Triflusal is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Triflusal is combined with Obinutuzumab.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Triflusal is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Triflusal.Approved
OtamixabanTriflusal may increase the anticoagulant activities of Otamixaban.Investigational
ParnaparinTriflusal may increase the anticoagulant activities of Parnaparin.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Triflusal.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Triflusal.Approved, Investigational
PhenindioneTriflusal may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonTriflusal may increase the anticoagulant activities of Phenprocoumon.Approved
PlasminTriflusal may increase the anticoagulant activities of Plasmin.Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Triflusal.Approved
Protein CTriflusal may increase the anticoagulant activities of Protein C.Approved
Protein S humanTriflusal may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTriflusal may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Triflusal.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Triflusal.Experimental, Investigational
ReteplaseTriflusal may increase the anticoagulant activities of Reteplase.Approved
ReviparinTriflusal may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Triflusal.Approved
RivaroxabanTriflusal may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneTriflusal may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Triflusal is combined with Salicylic acid.Approved, Vet Approved
SCH-530348SCH-530348 may increase the anticoagulant activities of Triflusal.Investigational
SelexipagTriflusal may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Triflusal.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Triflusal.Investigational
StreptokinaseTriflusal may increase the anticoagulant activities of Streptokinase.Approved
SulodexideTriflusal may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseTriflusal may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Triflusal.Investigational
TicagrelorTriflusal may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Triflusal.Approved
TinzaparinTriflusal may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Triflusal.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Triflusal.Approved
TositumomabThe risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.Approved
TranilastTranilast may increase the anticoagulant activities of Triflusal.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Triflusal.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Triflusal.Approved, Investigational
UrokinaseTriflusal may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Triflusal.Approved, Nutraceutical, Vet Approved
VorapaxarTriflusal may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinTriflusal may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTriflusal may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Triflusal may increase the anticoagulant activities of Ym150.Investigational
Food Interactions
  • Gingko bilboa
  • Herbs with anticoagulant/antiplatelet activity such as alfalfa, feverfew, ginger, ginseng, grape seed, green tea, horseradish
References
Synthesis ReferenceNot Available
General References
  1. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  2. Izquierdo I, Borja J, Rovira S, Pelagio P, Torres F, Cebrecos J, Garcia-Rafanell J: Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study. Arzneimittelforschung. 2010;60(1):36-41. doi: 10.1055/s-0031-1296246. [PubMed:20184225 ]
  3. Duran X, Sanchez S, Vilahur G, Badimon L: Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2. J Thromb Haemost. 2008 Aug;6(8):1385-92. doi: 10.1111/j.1538-7836.2008.03036.x. Epub 2008 May 22. [PubMed:18503633 ]
  4. Quetglas EG, Campanero MA, Sadaba B, Escolar M, Azanza JR: Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. Arzneimittelforschung. 2008;58(6):283-7. doi: 10.1055/s-0031-1296508. [PubMed:18677970 ]
  5. Gonzalez-Correa JA, De La Cruz JP: Triflusal: an antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev. 2006 Spring;24(1):11-24. [PubMed:16939630 ]
  6. Fraj J, Valero A, Vives R, Perez I, Borja J, Izquierdo I, Picado C: Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases. Allergy. 2008 Jan;63(1):112-5. [PubMed:18053020 ]
  7. Sanchez-Machin I, Garcia Robaina JC, Torre Morin F: Widespread eczema from triflusal confirmed by patch testing. Contact Dermatitis. 2004 Apr;50(4):257. [PubMed:15186390 ]
  8. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T: Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke. 2003 Apr;34(4):840-8. Epub 2003 Mar 20. [PubMed:12649515 ]
  9. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E: Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology. 2004 Apr 13;62(7):1073-80. [PubMed:15079004 ]
  10. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F: Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004296. [PubMed:16034926 ]
External Links
ATC CodesB01AC18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  2. Dominguez MJ, Vacas M, Saez Y, Olabarria I, Velasco A, Iriarte JA, Forn J: Effects of triflusal in patients with prosthetic heart valves. Clin Ther. 1985;7(3):357-60. [PubMed:3838919 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB1
Uniprot ID:
P19838
Molecular Weight:
105355.175 Da
References
  1. Zhang W, Potrovita I, Tarabin V, Herrmann O, Beer V, Weih F, Schneider A, Schwaninger M: Neuronal activation of NF-kappaB contributes to cell death in cerebral ischemia. J Cereb Blood Flow Metab. 2005 Jan;25(1):30-40. [PubMed:15678110 ]
  2. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  3. Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, Ferro JM, Gomez-Anson B, Manubens JM, Martinez-Lage JM, Munoz D, Pena-Casanova J, Torres F: A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):21-9. doi: 10.1097/WAD.0b013e3181611024. [PubMed:18317243 ]
  4. Whitehead SN, Bayona NA, Cheng G, Allen GV, Hachinski VC, Cechetto DF: Effects of triflusal and aspirin in a rat model of cerebral ischemia. Stroke. 2007 Feb;38(2):381-7. Epub 2006 Dec 28. [PubMed:17194886 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Molecular Weight:
131116.3 Da
References
  1. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  2. Sanchez de Miguel L, Casado S, Farre J, Garcia-Duran M, Rico LA, Monton M, Romero J, Bellver T, Sierra MP, Guerra JI, Mata P, Esteban A, Lopez-Farre A: Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils. Eur J Pharmacol. 1998 Feb 5;343(1):57-65. [PubMed:9551715 ]
  3. De Miguel LS, Jimenez A, Monton M, Farre J, Del Mar Arriero M, Rodriguez-Feo JA, Garcia-Canete J, Rico L, Gomez J, Nunez A, Casado S, Farre AL: A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest. 2000 Sep;30(9):811-7. [PubMed:10998082 ]
  4. Gonzalez-Correa JA, De La Cruz JP: Triflusal: an antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev. 2006 Spring;24(1):11-24. [PubMed:16939630 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:
PDE10A
Uniprot ID:
Q9Y233
Molecular Weight:
88411.71 Da
References
  1. McNeely W, Goa KL: Triflusal. Drugs. 1998 Jun;55(6):823-33; discussion 834-5. [PubMed:9617597 ]
  2. De Miguel LS, Jimenez A, Monton M, Farre J, Del Mar Arriero M, Rodriguez-Feo JA, Garcia-Canete J, Rico L, Gomez J, Nunez A, Casado S, Farre AL: A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest. 2000 Sep;30(9):811-7. [PubMed:10998082 ]
Comments
comments powered by Disqus
Drug created on June 28, 2011 23:05 / Updated on August 17, 2016 12:24